If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
590.00    2.00 (0.34%)
Bid:
586.00
Ask:
588.00
Spread: 2.00 (0.341%)
Market Cap: £514.04m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

US FDA approval: Total Knee Study

17 Sep 2024 14:00

RNS Number : 5569E
Victrex PLC
17 September 2024
 

17 September 2024

Victrex plc

US FDA Approval for Total Knee Arthroplasty Study in the US

Victrex plc is an innovative world leader in high performance polymer solutions, delivering sustainable products which support CO2 reduction and enable environmental and societal benefit in multiple end-markets.

The Group today announces that, in partnership with Maxx Orthopedics Inc, the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for Freedom® Total Knee System with Invibio PEEK-OPTIMA™ Femoral Component, as a staged study. The study, projected to be 120 patients at clinical sites in the US, will compare using the PEEK-OPTIMA™ Femoral Knee Component to a controlled registry of the same system using traditional metal femoral components.

 

The US study will build on the existing clinical trial for PEEK Knee at sites in Belgium, India and Italy, which has been progressing strongly since the first implant in 2021, with no clinical intervention. A regulatory submission in India is also expected imminently, supporting the potential for a commercial PEEK Knee in the market in 2025.

 

Jakob Sigurdsson, Chief Executive of Victrex, said: "PEEK Knee has the potential to be a game-changer for total knee replacement. Being able to further assess its benefits through rigorous clinical evaluation in the US will build on the strong progress so far through clinical trial sites in Europe and India. We look forward to the study's progression and remain optimistic about the transformative impact this pioneering device could have on the future of joint replacement.

 

"In relation to the regulatory submission in India, following a tenacious focus on innovation, development and investment to scale this significant opportunity, we now look forward to the potential for a PEEK Knee being in the market during 2025 and commercial revenues. We also continue to see growing interest in PEEK Knee from across the medical device industry, beyond our existing collaborations."

 

Victrex plc:

Andrew Hanson, Director of Investor Relations, Corporate Communications & ESG

+44 (0) 7809 595831

Jakob Sigurdsson, Chief Executive

+44 (0) 1253 897700

Ian Melling, Chief Financial Officer 

+44 (0) 1253 897700

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy & Industrial, Electronics and Medical. Every day, millions of people rely on products or applications which contain our sustainable materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 40 years' experience, we are moving beyond the polymer into semi-finished and finished products which shape future performance for our customers and our markets, enable environmental and societal benefit for our customers and drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFVFARIDLIS
Date   Source Headline
18th Oct 20194:01 pmRNSHolding(s) in Company
18th Oct 20192:20 pmRNSDirector/PDMR Shareholding
16th Oct 201911:04 amRNSAdditional Listing
11th Oct 20194:18 pmRNSHolding(s) in Company
8th Oct 20193:09 pmRNSHolding(s) in Company
7th Oct 20194:06 pmRNSHolding(s) in Company
3rd Oct 20194:18 pmRNSHolding(s) in Company
30th Sep 201911:53 amRNSTotal Voting Rights
18th Sep 20199:19 amRNSDirector/PDMR Shareholding
30th Aug 20199:00 amRNSTotal Voting Rights
19th Aug 201911:44 amRNSDirector/PDMR Shareholding
14th Aug 201910:39 amRNSHolding(s) in Company
31st Jul 20199:01 amRNSTotal Voting Rights
25th Jul 20197:00 amRNSInterim Management Statement
17th Jul 201910:38 amRNSDirector/PDMR Shareholding
28th Jun 20199:00 amRNSTotal Voting Rights
24th Jun 20197:00 amRNSDirectorate Change
18th Jun 201910:42 amRNSDirector/PDMR Shareholding
3rd Jun 20191:55 pmRNSBlock listing Interim Review
31st May 20193:12 pmRNSDirector/PDMR Shareholding
31st May 20199:00 amRNSTotal Voting Rights
20th May 201910:09 amRNSDirector/PDMR Shareholding
17th May 201910:50 amRNSDirector/PDMR Shareholding
15th May 20198:49 amRNSDirector/PDMR Shareholding
13th May 20197:00 amRNSHalf-year Report
30th Apr 201910:00 amRNSTotal Voting Rights
17th Apr 201912:03 pmRNSDirector/PDMR Shareholding
29th Mar 201912:07 pmRNSTotal Voting Rights
19th Mar 201910:55 amRNSDirector/PDMR Shareholding
28th Feb 20199:33 amRNSTotal Voting Rights
19th Feb 201910:42 amRNSDirector/PDMR Shareholding
18th Feb 20194:23 pmRNSDirector/PDMR Shareholding
11th Feb 20194:34 pmRNSHolding(s) in Company
8th Feb 20199:44 amRNSHolding(s) in Company
6th Feb 20192:28 pmRNSResult of AGM
6th Feb 20191:55 pmRNSDirector/PDMR Shareholding
6th Feb 20197:00 amRNSAGM and Q1 Interim Management Statement
4th Feb 201912:18 pmRNSDirector/PDMR Shareholding
31st Jan 20199:29 amRNSTotal Voting Rights
28th Jan 20194:28 pmRNSHolding(s) in Company
17th Jan 201911:21 amRNSDirector/PDMR Shareholding
11th Jan 20193:44 pmRNSHolding(s) in Company
3rd Jan 20191:00 pmRNSAnnual Financial Report
31st Dec 20189:00 amRNSTotal Voting Rights
18th Dec 20183:19 pmRNSDirector/PDMR Shareholding
18th Dec 201810:30 amRNSDirector/PDMR Shareholding
17th Dec 201811:40 amRNSDirector/PDMR Shareholding
11th Dec 20189:50 amRNSDirector/PDMR Shareholding
11th Dec 20189:48 amRNSDirector/PDMR Shareholding
5th Dec 20181:47 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.